Johnson Investment Counsel’s Sarepta Therapeutics SRPT Stock Holding History

Johnson Investment Counsel’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,373	Closed	-$215K	–	859
2025 Q1	$215K	Sell	3,373 -15	-0.4%	-$1.58K	﹤0.01%	739
2024 Q4	$412K	Buy	3,388 +240	+8%	+$29.4K	﹤0.01%	566
2024 Q3	$393K	Sell	3,148 -200	-6%	-$27.6K	﹤0.01%	563
2024 Q2	$529K	Hold	3,348	–	–	0.01%	481
2024 Q1	$433K	Sell	3,348 -4	-0.1%	-$490	﹤0.01%	532
2023 Q4	$323K	Hold	3,352	–	–	﹤0.01%	568
2023 Q3	$406K	Sell	3,352 -300	-8%	-$33.9K	0.01%	497
2023 Q2	$418K	Buy	3,652 +19	+0.5%	+$2.45K	0.01%	508
2023 Q1	$501K	Hold	3,633	–	–	0.01%	458
2022 Q4	$471K	Sell	3,633 -1,200	-25%	-$139K	0.01%	463
2022 Q3	$534K	Sell	4,833 -9,500	-66%	-$958K	0.01%	425
2022 Q2	$1.07M	Sell	14,333 -1,948	-12%	-$143K	0.02%	318
2022 Q1	$1.27M	Buy	+16,281	New	+$1.25M	0.02%	306
2021 Q1	–	Sell	-1,500	Closed	-$256K	–	623
2020 Q4	$256K	Buy	+1,500	New	+$222K	﹤0.01%	521

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Johnson Investment Counsel's SRPT Position: Q2 2025 in Review

Johnson Investment Counsel sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 3,373 shares — an estimated $215K sold.

Johnson Investment Counsel first reported a position in SRPT in Q4 2020 and held it in 14 quarters. The position peaked at $1.27M in Q1 2022. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Johnson Investment Counsel reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Johnson Investment Counsel sold 3,373 Sarepta Therapeutics shares in Q2 2025, an estimated $215K.
Johnson Investment Counsel first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 14 quarters.
Johnson Investment Counsel's Sarepta Therapeutics position peaked at $1.27M in Q1 2022.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Johnson Investment Counsel's 13F filing for Q2 2025, filed 25 Jul 2025.